IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines

October 2020 | Volume 19 | Issue 10 | Original Article | 985 | Copyright © October 2020

Published online September 30, 2020

Martina Kerscher PhDa, Sabrina Fabi MDb, Tanja Fischer MDPhD, Michael Gold MDd, John Joseph MDe, Welf Prager MDf, Berthold Rzany MD ScMg, Steve Yoelin MDh, Susanna Roll Dr. med, Gudrun Klein PhDi, Corey Maas MD PhDj

aUniversität Hamburg, Hamburg, Germany bCosmetic Laser Dermatology, San Diego, CA cHaut- & Lasercentrum, Potsdam, Germany dGold Skin Care Center, Tennessee Clinical Research Center, Nashville, TN eJohn Joseph MD, Private Practice, Beverly Hills, CA fPrager and Partner Dermatologische Praxis, Hamburg, Germany gHautärzte RZANY&HUND, Berlin, Germany hMedical Associates, Inc., Newport Beach, CA iMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany jThe Maas Clinic, San Francisco, CA

5. Kane MA, Gold MH, Coleman WP, 3rd, et al. A Randomized, Double- Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines. Dermatol Surg. 2015;41(11):1310-1319.
6. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36 Suppl 4:2146-2154.
7. Carruthers A, Carruthers J, Coleman WP, 3rd, et al. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013;39(4):551-558.
8. Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg. 2013;39(6):891-899.
9. Jones D, Carruthers J, Narins RS, et al. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials. Dermatol Surg. 2014;40(7):776-785.
10. Polacco M, Singleton A, Barnes C, MD, et al. A Double-Blind, Randomized Clinical Trial to Determine Effects of Increasing Doses and Dose-Response Relationship of IncobotulinumtoxinA in the Treatment of Glabellar Rhytids. Aesthet Surg J. 2020 Jul 28; sjaa220. doi: 10.1093/asj/sjaa220. Online ahead of print.
11. Honeck P, Weiss C, Sterry W, et al. Reproducibility of a fourpoint clinical severity score for glabellar frown lines. Br J Dermatol. 2003;149:306–10.
12. Sloop RR, Escutin RO, Matus JA, et al. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology. 1996;46(5):1382-6.
13. Wohlfarth K, Muller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol. 2007;30(2):86-94.
14. Joseph JH, Eaton LL, Robinson J, et al. Does increasing the dose of abobotulinumtoxin A impact the duration of effectiveness for the treatment of moderate to severe glabellar lines? J Drugs Dermatol. 2016;15(2):1544- 1549.
15. Keller JE. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience. 2006;139(2):629-37.
16. Pellett S, Bradshaw M, Tepp WH, et al. The light chain defines the duration of action of botulinum toxin serotype A subtypes. mBio. 2018;9(2):e00089-18.
17. Allergan Aesthetics Day Press Release September 14, 2018.
18. Carruthers J, Solish N, Humphrey S, et al. Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatol Surg. 2017;43(11):1321-1331.
19. Carruthers JD, Fagien S, Joseph JH, Humphrey SD at al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
20. Prager W, Rappl T. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines. J Cosmet Dermatol. 2012 Dec;11(4):267-71.
21. Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800U in limb spasticity: The TOWER study. Neurology. 2017;88(14):1321-1328.
22. Coleman WP, Sattler G, Weissenberger P et al. Safety of incobotulinumtoxinA in the Treatment of Facial Lines: Results From a Pooled Analysis of randomized, prospective, controlled clinical studies. Dermatol Surg. 2017;43:S293–S303.
23. Kazerooni, R. Decreased therapeutic effect over time amongst botulinum toxin type A agents. Mov Disord Clin Pract. 2020;7(S1):S10(110).
24. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1-9.
25. Frevert J, Ahn KY, Park MY, et al. Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;11:327-331.
26. Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, et al. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring. J Cosmet Dermatol. 2018;17(6):984-990.
27. Zhang L, Lin WJ, Li S, Aoki KR. Complete DNA sequences of the botulinum neurotoxin complex of clostridium botulinum type A-Hall (Allergan) strain. Gene. 2003;315:21-32.Frevert J. Drugs R D. 2010;10(2):67-73.
28. Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, et al. IncobotulinumtoxinA: a highly purified and precisely manufactured botulinum neurotoxin type A. J Drugs Dermatol. 2019;18(1):52-57.
29. Xie J, Bi Y, Zhang H, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020;11:697.
30. Prawdzik G, Oliyai C, Joshi A. Nonclinical overview of daxibotulinumtoxinA for injection to support registration for human use. Poster presented at: “TOXINS 2019 Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins.” 2019;Copenhagen, Denmark.
31. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743-1746.
32. Solish N, Bertucci V, Humphrey S, et al. Two phase 3, randomized doubleblind, placebo controlled, multi-center trials to evaluate the efficacy and safety of daxibotulinumtoxinA for injection to treat moderate to severe glabellar lines (SAKURA 1 and 2). Annual Meeting of the American Academy of Dermatology. February 16-20, 2018: Poster 7490.
33. Fabi S, Cohen J, Green L, et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, openlabel, phase 3 safety study. Dermatol Surg. 2020; Online ahead of print.


Martina Kerscher MD PhD